Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (OP:TLTFF)

0.1342 -0.0068 (-4.82%)
Delayed Quote Updated: 1:04 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theralase Technologies Inc

< Previous 1 2 3 4 Next >
News headline image
Theralase Provides Bladder Cancer Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the... 
Via Newsfile
News headline image
Theralase(R) to Present at ThinkEquity Conference
Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical... 
Via Newsfile
News headline image
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Theralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology PipelineThis Press Release adds omitted safety and... 
Via Newsfile
News headline image
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline 
Via Newsfile
News headline image
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Lists Warrants on the TSXV
Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Releases Q1 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the... 
Via Newsfile
News headline image
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
News headline image
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical... 
Via Newsfile
News headline image
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past.Toronto, Ontario--(Newsfile... 
Via Newsfile
News headline image
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress ↗
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
News headline image
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with... 
Via Newsfile
News headline image
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Investor Conference Call Reminder
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Releases 3Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering... 
Via Newsfile
News headline image
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
Topics Derivatives
News headline image
Theralase(R) Extends Warrants
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
News headline image
Theralase(R) Releases 2Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage... 
Via Newsfile
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.